Citations 1
Antibodies as drugs—a Keystone Symposia report
Cable, Jennifer, Wiltshire, Timothy D. , Mousa, Jarrod J. , Humphreys, David P., Breij, Esther C.W. , Bruhns, Pierre , Broketa, Matteo , Furuya, Genta , Hauser, Blake M. , Mahévas, Matthieu , Kwong, Peter D. , Davis, Jonathan H. , Brewis, Neil , Keyt, Bruce A. , Fennemann, Felix L. , Dussupt, Vincent , Rawi, Reda , Wolters, Rachael M. , Geuijen, Cecile, Sleeman, Matthew A. , Pengo, Niccolò , Donnellan, Francesca R. , Saphire, Erica Ollmann , Hayday, Adrian , Carfı́, Andrea , Cantaert, Tineke , Tripathi, Prabhanshu , Sivasubramanian, Arvind, Kim, Philip M. , Richardson, Eve , Leventhal, Daniel
Annals of the New York Academy of Sciences | November 16, 2022 | Volume: 1519 | Issue: 1 | Pages: 153-166
AbstractTherapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27–30, 2022, experts in antibody research across academia and industry met for the Keystone symposium “Antibodies as Drugs” to present the state‐of‐the‐art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering.